Skip to main content
Proceeding dossierAdministrative caseLatest encoded: Remedy

FTC insulin-rebate administrative matter

The FTC administrative complaint and the currently encoded proposed consent agreements involving pharmacy benefit managers and affiliated group purchasing organizations.

Grouping basisThe complaint and two proposed consent agreements are grouped by their shared FTC administrative matter, Docket No. 9437; the broader PBM market study remains separate.

Exact official-record sequence

1.8 years / 662 days

3 encoded points
FTC insulin-rebate administrative matter official-record timeline3 exact dated official records from Sep 20, 2024 through Jul 14, 2026. The latest point is the latest encoded record, not a legal-status determination.Sep 20, 2024Jul 14, 2026012024-09-20Litigation2024-09-20 / Litigation / FTC files administrative complaint against the three largest PBMs022026-02-04Remedy2026-02-04 / Remedy / FTC announces proposed consent agreement with Express Scripts032026-07-14Remedy2026-07-14 / Remedy / FTC announces proposed consent agreement with CaremarkOfficial record date / no interpolation
First encoded recordLatest encoded stage: Remedy
Official records
31.8 years / 662 days
Named organizations
610 exact record edges
Market contexts
13 HHI windows
Source dossiers
31 record publisher
  • Identityproceeding-pbm-insulinExplicit editorial membership
  • Temporal unit2024-09-20 / 2026-07-14Exact record dates
  • Current edgeRemedyLatest encoded, not legal status
  • Permitted inferenceChronology + contextNo automatic legal or causal claim

Official-record chronology

What is encoded, in exact sequence

Sep 20, 2024 to Jul 14, 2026
012024-09-20
LitigationComplaint

FTC files administrative complaint against the three largest PBMs

The FTC brought an administrative action alleging anticompetitive and unfair rebating and formulary practices involving Caremark, Express Scripts, OptumRx, and affiliated GPOs.

Adds alleged conduct and patient-harm context to the PBM profile. The allegations remain distinct from the descriptive concentration evidence and do not supply missing individual shares.
022026-02-04
RemedySettlement

FTC announces proposed consent agreement with Express Scripts

The FTC announced a proposed consent agreement with Express Scripts and affiliated entities addressing formulary design, patient cost sharing, manufacturer compensation, plan-sponsor transparency, community-pharmacy reimbursement, and related business practices.

Records announced remedy terms in the pending administrative matter. The filing does not establish realized savings, changes in PBM market structure, or a basis for calculating the withheld market HHI.
Agency / court
Federal Trade Commission
Docket
Docket No. 9437
Named edges
2
Market contexts
1
032026-07-14
RemedySettlement

FTC announces proposed consent agreement with Caremark

The FTC announced a proposed consent agreement with Caremark and Zinc Health Services addressing formulary design, point-of-sale rebates, fee structures, plan-sponsor transparency, community-pharmacy reimbursement, and access to pharmacy hub services.

Records announced remedy terms in the pending administrative matter. The filing does not establish realized savings, changes in PBM market structure, or a basis for calculating the withheld market HHI.
Agency / court
Federal Trade Commission
Docket
Docket No. 9437
Named edges
2
Market contexts
1

Intervals between points indicate elapsed calendar time only. They do not imply inactivity, continuous litigation, completion, or a causal sequence.

Declared proceeding network

Organizations and markets named around the chronology

10 exact organization-record edges

Named organizations

6 unique labels

Bounded market contexts

1 separately defined profiles

A market link is observatory context assigned to an official record. It is not necessarily the relevant antitrust market alleged or adjudicated in the proceeding.

Descriptive economic windows

Public HHI anchors around each dated record

0 paired / 0 partial / 3 unavailable
HHI unavailable2026-07-14PBMs
Strict pre
UnavailableNo earlier anchor
Event year
UnavailableNo same-year anchor
Strict post
UnavailableNo later anchor
Pre-post delta
Not availablePair unavailable
HHI unavailable2026-02-04PBMs
Strict pre
UnavailableNo earlier anchor
Event year
UnavailableNo same-year anchor
Strict post
UnavailableNo later anchor
Pre-post delta
Not availablePair unavailable
HHI unavailable2024-09-20PBMs
Strict pre
UnavailableNo earlier anchor
Event year
UnavailableNo same-year anchor
Strict post
UnavailableNo later anchor
Pre-post delta
Not availablePair unavailable

These are descriptive observations from separately defined market series. Timing does not identify the proceeding's effect, and missing HHI remains missing.

Source custody

Official sources behind the sequence

3 source records

Declared-context neighborhood

1 exact overlap route

Shared observatory context does not establish that two proceedings concern the same conduct, parties, legal theory, market, or effect.

Reproducible proceeding packet

Reuse the chronology without flattening its evidence

Every route keeps the exact event IDs selected for this proceeding. Record rows, named-organization edges, market windows, and Atlas relationships remain separate tables.

Proceeding ID
proceeding-pbm-insulin
Profile slug
pbm-insulin-rebate-case
Docket set
Docket No. 9437
License
CC BY 4.0 compilation

Proceeding interpretation boundary

The complaint and two proposed consent agreements are grouped by their shared FTC administrative matter, Docket No. 9437; the broader PBM market study remains separate. The latest encoded stage is a data-coverage statement, not a conclusion about current posture or finality.

Evidence standard